IGF-1 DES
Unapproved IGF-1 variant — not FDA-approved.
What it's for
IGF-1 DES is a shortened research version of IGF-1 that lacks the first three building blocks of the natural hormone. Researchers describe that change as reducing binding to some IGF-binding proteins. It is not FDA-approved.
What it does for the body
It shows up in performance and research conversations for possible localized growth effects. It is not FDA-approved. Mecasermin (full-length lab-made IGF-1) is the approved IGF-1 drug for a rare pediatric use — a different product.
What it targets
Like IGF-1, it is discussed as turning on IGF-1 growth receptors on cells, with research suggesting it interacts differently with IGF-binding proteins than natural IGF-1. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: IGF-1 DES is best treated as a research-interest topic. Early papers can be fascinating; they are not a green light for self-experimentation.
Studied for (literature interest)
- Bones research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: IGF-1 DES — FDA.gov search
- ClinicalTrials.gov search: IGF-1 DES — U.S. clinical trials registry
- Drugs@FDA search: IGF-1 DES — FDA drug database (if approved)
- PubMed search: IGF-1 DES — NCBI PubMed
- PubMed Central search: IGF-1 DES — NCBI PMC
Reference
No ref on file.